HC Wainwright Has Weak Outlook for Precigen FY2025 Earnings

Key Points

• HC Wainwright has reduced its FY2025 earnings per share (EPS) estimate for Precigen from ($0.26) to ($0.31), maintaining a "Buy" rating with a target price of $6.00.
• Precigen reported quarterly earnings of ($0.11) per share, beating expectations of ($0.14), while revenues reached $0.86 million, surpassing forecasts of $0.67 million.
• Precigen's stock has seen significant growth, trading up 58.9% recently, and currently has an average rating of "Moderate Buy" among analysts.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Analysts at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for shares of Precigen in a research note issued on Wednesday, August 13th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings per share of ($0.31) for the year, down from their previous forecast of ($0.26). HC Wainwright currently has a "Buy" rating and a $8.50 target price on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share.

A number of other research analysts have also recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Precigen in a research note on Thursday, May 15th. Citigroup reaffirmed an "outperform" rating on shares of Precigen in a research note on Tuesday. JPMorgan Chase & Co. raised Precigen from an "underweight" rating to a "neutral" rating in a research note on Friday, August 15th. JMP Securities upped their target price on Precigen from $6.00 to $8.00 and gave the company a "market outperform" rating in a research note on Tuesday. Finally, Wall Street Zen raised shares of Precigen from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $8.25.

Precigen Price Performance

Shares of PGEN traded up $0.54 during mid-day trading on Monday, reaching $4.18. 24,184,755 shares of the company's stock traded hands, compared to its average volume of 14,296,194. The stock has a market cap of $1.25 billion, a P/E ratio of -9.95 and a beta of 1.87. The stock's 50-day moving average is $1.87 and its two-hundred day moving average is $1.67. Precigen has a 12 month low of $0.65 and a 12 month high of $4.21.

Precigen (NASDAQ:PGEN - Get Free Report) last released its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.86 million for the quarter, compared to analysts' expectations of $0.67 million. Precigen had a negative return on equity of 842.83% and a negative net margin of 2,868.66%.

Institutional Trading of Precigen

Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new stake in shares of Precigen during the fourth quarter valued at approximately $27,000. Envestnet Asset Management Inc. boosted its stake in shares of Precigen by 29.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 5,915 shares in the last quarter. Boothbay Fund Management LLC bought a new position in shares of Precigen during the fourth quarter valued at approximately $35,000. Apella Capital LLC bought a new position in shares of Precigen during the first quarter valued at approximately $40,000. Finally, Invesco Ltd. boosted its stake in shares of Precigen by 14.6% during the fourth quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 6,040 shares in the last quarter. Institutional investors own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.